Encima in the News: Archive
For Immediate Release, 09.14.2011
Mobile marketing: Think before going all in
Source: World of DTC Marketing
Once again we are seeing a wealth of research on the use of mobile by consumers to surf the Internet. DUH. The reason that so many people are using mobile is that they can use it to fight off boredom of sitting in meetings, sitting in their morning commutes or just to better manage time in a time compressed world. However the bad news is that according to Med Ad News none of the top 15 pharma sites is optimized for mobile browsers. This is totally unacceptable.
For Immediate Release, 08.23.2011
Contract Manufacturing Is Forecast to Explode
Source: Pharmalot
With all the outsourcing that drugmakers have undertaken in recent years, it should come as no surprise that contract manufacturing, in particular, is forecast to mushroom over the next several years. To be specific, revenue from this activity is expected to hit $64 billlion by 2016 and more than double between now and 2021, according to a report from Visiongain.
For Immediate Release, 08.22.2011
Good DTC marketers don’t look for recognition
Source: World of DTC Marketing
I know a lot of people in the pharma marketing business and I have to say that none of them are in DTC marketing because they are looking for “recognition”. They are in the business, for the most part, because it offers them a challenge and they believe in what they are doing. If you’re looking for recognition and for a lot of pats on the back you’re not only in the wrong industry you’re in the wrong profession.
For Immediate Release, 08.03.2011
Sure consumers are using social media for health but…
Source: World of DTC Marketing
According to a post in this mornings eMarketer “In its April 2011 survey, Deloitte Center for Health Solutions found that 11% of US healthcare consumers use social networks to find or share health information and 8% use blogs. The respondents who use blogs and social networks for health purposes do so to comment about the healthcare system, to comment about doctors and hospitals and to share personal healthcare experiences with others.” The question then becomes who do they want in the “health conversation“?
For Immediate Release, 08.02.2011
Point-of-Care Pharma Marketing: When Is It Appropriate?
Source: Pharma Marketing Blog
In the world of smartphone apps for physicians, Epocrates plays a leading role. The Epocrates iPhone app is free (with a $99 PREMIUM upgrade option) to physicians -- and anyone else -- who can use the app to find information on drug dosing, interactions and insurance coverage while seeing a patient. According to a New York Times article (see here), 70% of Epocrates' revenue comes from pharma point-of-care advertising; ie, messages from pharma advertisers that pop up as "DocAlerts" when the app is used to look up drugs, etc.
For Immediate Release, 07.28.2011
Do all brands have to lose 90% of sales to generics ? Not necessarily
Source: World of DTC Marketing
The US Pharma industry often regards drugs with generic competition to be at the end of their promotional lifetimes. As we prepare for an onslaught of new generics over the next 18 months, Cegedim explores how generics have impacted promotional strategy for some of America’s most prescribed molecules. Despite active generic competition, Pfizer’s blood pressure medication Norvasc is still actively promoted through a variety of channels as is Merck’s lipid-lowering drug Zocor. Much smaller on the promotion scale is BMS’ Glucophage which barely outspends its generic competitors.
For Immediate Release, 07.26.2011
Clinical Trial Costs Are Rising Rapidly
Source: Pharmalot
As drugmakers scramble to replenish their pipelines, they are encountering all sorts of difficulties, including rising costs for clinical trials. And this is happening across all phases. Why? There is increasing competition for trial sites and clinical research organizations that can yield reliable, high quality data, according to a recent survey.
For Immediate Release, 07.09.2011
Pharma in cross hairs of budget debate
Source: World of DTC Marketing
Democrats have targeted pharmaceutical profits as a means of raising revenue as part of the debt ceiling deal, Chris Van Hollen, the top Democrat on the Budget Committee, said Friday.
For Immediate Release, 07.08.2011
Pharma Is Pouring Marketing $ Into China
Source: Pharmalot
As drugmakers reevaluate their sales and marketing spending in the US, those dollars are being shifted to Asia, notably China, and Latin America. For instance, spending on meetings and other events rose slighty more than 5 percent worldwide last year to $13 billion. And this amounts to 14 percent of global spending on marketing, according to Cegedim Strategic Data.
For Immediate Release, 02.01.2010
The Encima Group To Exhibit at the ePharma Summit
The Encima Group, a marketing services consulting firm serving the bio-pharmaceutical industry, is proud to be an exhibitor at the upcoming ePharma Summit, February 8-10 at the Hyatt Regency in Philadelphia, PA. "We're excited to meet and speak with marketers & e-Channel professionals at the premier event for online and digital marketing in the pharmaceutical industry," said David Clunes, President.
For Immediate Release, 12.16.2008
Encima Group's Consultants Reach the Universe of Expertise
The Encima Group, a consulting network focused on successful outcomes for clients' marketing initiatives, continues to expand its vertical presence beyond that of your typical strategic services firm. David Clunes, President, is committed to building a team that is knowledgeable in all facets of marketing and data analysis across specialties. David describes this focus on quality and breadth of expertise as "an essential element of the strategic process that allows us to readily anticipate and react to market conditions across verticals."
For Immediate Release, 11.24.2008
The Encima Group is Serious About Strategy
The Encima Group, regarded as a premier marketing solutions firm, is dedicated to helping clients achieve measurable success by staying true to their core strategic focus. "Our company is strategy-driven," said David Clunes, President, "from front end campaign development to back end analysis."
For Immediate Release, 10.15.2008
The Encima Group Fosters Their Unique Position as a Supplemental Strategy Vendor
Vendor selection just got easier as The Encima Group continues to carve out their unique role as a supplemental strategy group for a company’s marketing initiatives. David Clunes, President, a pharmaceutical marketing veteran, has worked tirelessly hand selecting a team of seasoned consultants with deep expertise across verticals and discliplines. “I have built The Encima Group on the foundation of marketing success,” remarks David, “so it’s critical that I find category experts who can bring highly targeted, actionable insights to clients’ projects to drive positive, tangible results.” The company currently specializes in pharmaceutical and healthcare marketing, but with consultant experts in a wide variety of industries, they are well equipped to handle any subject or vertical.
For Immediate Release, 9.15.2008
The Encima Group Launches New Website To Reflect Unique Expertise and Core Specialties
The Encima Group, a strategic consulting firm known for their ability to refine and re-ignite marketing programs for maximum success, has revamped their website in support of their full suite of services with an emphasis on Internet Marketing and Analytics. “Internet Marketing has always been a core strength,” remarks David Clunes, President, “but our online business has been expanding, and as a result, our network of consultants has grown considerably, bringing an even greater web expertise to the mix. I wanted the new site to reinforce our strategic positioning around Internet Marketing but also highlight the other services that make us a unique partner for clients, such as Marketing Operations and Relationship Marketing.” With consultants that span the country, The Encima Group is able to offer clients a comprehensive set of niche offerings, all designed to improve campaign effectiveness.